Page last updated: 2024-12-06

4-methoxyamphetamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-methoxyamphetamine: para-methoxy derivative to amphetamine with hallucinogenic properties; minor descriptor (75-86); on line & INDEX MEDICUS search AMPHETAMINES (75-86); RN given refers to parent compound without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID31721
CHEMBL ID278663
SCHEMBL ID264634
SCHEMBL ID721008
MeSH IDM0263095

Synonyms (94)

Synonym
benzenethanamine,4-methoxy-.alpha.-methyl-(.+/-.)-
phenethylamine, p-methoxy-.alpha.-methyl-, (.+/-.)-
2-amino-1-(4'-methoxyphenyl)propane
.alpha.-methyl-.beta.-(p-methoxyphenyl)ethylamine
1-p-methoxyphenyl-2-aminopropane
phenethylamine, p-methoxy-.alpha.-methyl-
benzeneethanamine, 4-methoxy-.alpha.-methyl-
nsc-32757
64-13-1
1-p-methoxyphenyl-2-propylamine
nsc32757
NCI60_002842
dea no. 7411
(+-)-p-methoxyamphetamine
(+/-)-1-(p-methoxyphenyl)-2-aminopropane
(+/-)-4-methoxyamphetamine
p-methoxyamphetamine
benzeneethanamine, 4-methoxy-alpha-methyl- (9ci)
alpha-methyl-beta-(p-methoxyphenyl)ethylamine
4-methoxy-alpha-methylbenzeneethanamine
p-methoxy-alpha-methylphenethylamine
2-(4-methoxyphenyl)-1-methylethylamine
(+/-)-p-methoxy-alpha-methylphenylethylamine
dl-p-methoxy-alpha-methylphenethylamine
1-(4-methoxybenzyl)ethylamine
(d,l)-4-methoxyamphetamine
phenethylamine, p-methoxy-alpha-methyl- (6ci,7ci,8ci)
benzeneethanamine, 4-methoxy-alpha-methyl-
4-methoxyamphetamine
(+/-)-p-methoxyamphetamine
paramethoxyamphetamine
4-methoxyamfetamine
DB01472
(2rs)-1-(4-methoxyphenyl)propan-2-amine
d,l-p-methoxyamphetamine
p-methoxyamfetamine
NCGC00168268-01
para-methoxyamphetamine
1-(4-methoxyphenyl)propan-2-amine
beta-methoxyamphetamine
CHEMBL278663 ,
FT-0690314
STK664902
(-)2-(4-methoxy-phenyl)-1-methyl-ethylamine
(r)-(-)2-(4-methoxy-phenyl)-1-methyl-ethylamine
bdbm50024209
(s)-(+)2-(4-methoxy-phenyl)-1-methyl-ethylamine
(+/-)2-(4-methoxy-phenyl)-1-methyl-ethylamine
2-(4-methoxy-phenyl)-1-methyl-ethylamine(pma)
2-(4-methoxy-phenyl)-1-methyl-ethylamine
[2-(4-methoxyphenyl)-1-methyl-ethyl]-amine
AKOS005536031
(+-)-4-methoxyamphetamine
(+-)-p-methoxy-alpha-methylphenylethylamine
unii-ovb8f8p39q
chicken powder [street name]
ovb8f8p39q ,
einecs 200-577-0
hsdb 7594
nsc 32757
death [street name]
(+-)-1-(p-methoxyphenyl)-2-aminopropane
chicken yellow [street name]
phenethylamine, p-methoxy-alpha-methyl-
23239-32-9
formoterol fumarate dihydrate impurity g [ep impurity]
death
dr. death
4-methoxyamfetamine [mart.]
j434.573h
j213.549c ,
pma (psychedelic)
SCHEMBL264634
SCHEMBL721008
AB51426
(1s)-2-(4-methoxyphenyl)-1-methylethylamine
AB70588
MB01555
1-(4-methoxyphenyl)-2-aminopropane
(-)-2-(p-methoxyphenyl)-1-methylethylamine
alpha-methyl-4-methoxyphenethylamine
n-(2-(p-methoxyphenyl)-1-methylethyl)amine
(.+/-.)-1-(p-methoxyphenyl)-2-aminopropane
(.+/-.)-p-methoxyamphetamine
dl-p-methoxy-.alpha.-methylphenethylamine
1-(4-methoxyphenyl)-2-propanamine
p-methoxy-.alpha.-methylphenethylamine
(.+/-.)-4-methoxyamphetamine
(.+/-.)-p-methoxy-.alpha.-methylphenethylamine
benzeneethanamine, 4-methoxy-.alpha.-methyl-, (.+/-.)-
DTXSID7040578
chloroprednisone21-acetate
Q230005
formoterol fumarate impurity g

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In other trials, prior treatment with diethylcarbamazine (DEC) was found to potentiate the lethality of FN, while cyproheptadine (CHP) pretreatment attenuated FN's toxic effects."( A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat.
Hunsinger, RN; Wright, D,
)
0.13
" The findings suggest that 4-substituted amphetamines exhibit a wide variation in their effects on maternal toxicity and pregnancy wastage, and produce adverse effects on parturition, pup survival, and postnatal development."( Developmental toxicity of 4-substituted amphetamines in mice.
Buttar, HS; Foster, BC; Moffatt, JH,
)
0.13
" The requirements of safe practice, the shift accountability, the ethical aspects and forthcoming changes in the regulatory constraints are discussed."( Radiation safety when a patient dies after therapy.
Blais, M; Bybel, B; Driedger, AA; Vandierendonck, R, 1998
)
0.3
" Wanting to estimate the risk of death from bleeding or perforated gastroduodenal ulcers with chronic usage of non-steroidal anti-inflammatory drugs (NSAIDs) with greater precision, we developed a model to quantify the frequency of rare adverse events which follow a biological progression."( Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use.
McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 2000
)
0.31
" In a re-examination of the effect of boron on the embryo-larval stage in rainbow trout and zebrafish, adverse effects due to boron deficiency are observed which decrease with increasing dose."( Toxicity of boron to rainbow trout: a weight-of-the-evidence assessment.
Loewengart, G, 2001
)
0.31
" Post-marketing surveillance provides the opportunity to assess a drug's safety in every day clinical conditions in a much greater patient population than in clinical trials and therefore serves as a useful tool to detect signals for adverse effects with an incidence of less than 1 : 10,000."( Fluvoxamine: safety profile in extensive post-marketing surveillance.
Buchberger, R; Wagner, W, 2002
)
0.31
" Meta-analyses evaluated effectiveness and adverse side effects for one-month administrations of aspirin plus cilostazol or aspirin plus ticlopidine therapy after coronary stenting."( Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004
)
0.32
" While, the incidence of adverse side effects tended to be lower, they were not statistically significant in patients with aspirin plus cilostazol."( Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004
)
0.32
" chebula ethanol extracts gave no adverse effects at dosages of 2000 mg/kg in rats in the study."( Mutagenicity and oral toxicity studies of Terminalia chebula.
Hong, CO; Jun, W; Kim, JH; Koo, YC; Lee, KW; Yang, SY, 2012
)
0.38
"Serious adverse events in research involving healthy volunteers are rare, but their impact on other volunteers is unknown."( When a serious adverse event in research occurs, how do other volunteers react?
Flexner, C; Fuchs, EJ; Kass, N; Kennedy, CE; Myers, RK, 2011
)
0.37
"9% and rate of major adverse cardiac events, a composite of cardiac death, MI, target lesion revascularization (TLR) and coronary artery bypass graft, was 11."( Safety and efficacy of the cobalt chromium PRO-Kinetik coronary stent system: results of the MULTIBENE study.
Agostoni, P; Appelman, Y; Boland, J; Buysschaert, I; Castadot, M; Coussement, P; Horstkotte, D; Janssens, L; Lalmand, J; Richardt, G; Suttorp, MJ; Vermeersch, P,
)
0.13
"Based on these data, the PRO-Kinetik coronary stent system was found to be safe and effective."( Safety and efficacy of the cobalt chromium PRO-Kinetik coronary stent system: results of the MULTIBENE study.
Agostoni, P; Appelman, Y; Boland, J; Buysschaert, I; Castadot, M; Coussement, P; Horstkotte, D; Janssens, L; Lalmand, J; Richardt, G; Suttorp, MJ; Vermeersch, P,
)
0.13
"This analysis was conducted to clarify risk factors for severe adverse effects and treatment-related deaths reported during a postmarketing survey of irinotecan."( Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J, 2013
)
0.39
" The patient background data and adverse drug reactions were collected through case report forms."( Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J, 2013
)
0.39
" Major grade 3-4 adverse drug reactions were leukopenia (34."( Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J, 2013
)
0.39
" The major outcomes were target lesion revascularization (TLR) and major adverse cardiac events (MACE)."( Comparative efficacy and safety of drug-eluting stent and conventional therapies in coronary heart disease patients with in-stent restenosis: a meta-analysis.
Li, L; Lu, Y; Su, Q; Sun, Y, 2014
)
0.4
" We assess the effectiveness of Steering Teens Safe, a parent-focused program to increase safe teen driving."( Steering teens safe: a randomized trial of a parent-based intervention to improve safe teen driving.
Cavanaugh, JE; Chande, V; Peek-Asa, C; Ramirez, M; Yang, J; Young, T, 2014
)
0.4
"Steering Teens Safe aimed to improve parental communication with teens about safe driving using motivational interviewing techniques in conjunction with 19 safe driving lessons."( Steering teens safe: a randomized trial of a parent-based intervention to improve safe teen driving.
Cavanaugh, JE; Chande, V; Peek-Asa, C; Ramirez, M; Yang, J; Young, T, 2014
)
0.4
" Purified Ymt is highly toxic to mice and rats, but the exact mechanism of the animals' death is unclear."( Recombinant murine toxin from Yersinia pestis shows high toxicity and β-adrenergic blocking activity in mice.
Bi, Y; Fan, Y; Feng, N; Liu, Z; Tian, G; Wang, Q; Wang, X; Wu, X; Yang, R; Zhou, Y, 2016
)
0.43
"Improper disposal of dead pigs by pig farmers may have an adverse impact on the ecological environment and food safety."( Influential impacts of combined government policies for safe disposal of dead pigs on farmer behavior.
Chen, X; Hu, W; Qiu, G; Wang, J; Wu, L; Xu, G, 2017
)
0.46
" Vultures exposed to carprofen as residues in the kidney tissue or pure drug equivalents showed no toxic signs."( The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures.
Chipangura, J; Duncan, N; Galligan, TH; Green, RE; Naidoo, V; Taggart, MA; Wolter, K, 2018
)
0.48
" No significant adverse events were noted with C1INH."( A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.
Ammerman, N; Aubert, O; Choi, J; Haas, M; Huang, E; Jordan, SC; Kim, I; Louie, S; Loupy, A; Najjar, R; Peng, A; Puliyanda, D; Vo, A, 2018
)
0.48
"to describe the adverse events related to health care resulting in death."( Registry of adverse events related to health care that results in deaths in Brazil, 2014-2016.
Araújo, WN; Freitas, DRC; Gallo, LG; Maia, CS, 2018
)
0.48
" 1219 (40·9%) of 2983 patients in the trimetazidine group and 1230 (41·1%) of 2990 patients in the placebo group had serious treatment-emergent adverse events."( Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
Challeton, JP; Correges, A; Danchin, N; Ferrari, R; Ford, I; Fox, K; Tendera, M; Widimský, P, 2020
)
0.56
" The safety outcomes included major adverse cardiovascular events, target vessel revascularization, myocardial infarction, definite or probable scaffold thrombosis, and cardiac death."( Efficacy and safety of bioresorbable scaffolds in patients with coronary bifurcation lesions: A systematic review and meta-analysis.
Li, Y; Liang, XY; Qiao, X; Wang, ZL; Yang, RR; Zhang, WJ, 2022
)
0.72
" Our objectives were to assess the prevalence of frailty parameters in middle-aged individuals and probe the association with future adverse events."( Several frailty parameters highly prevalent in middle age (50-65) are independent predictors of adverse events.
Bastuji-Garin, S; Broussier, A; David, JP; Fromentin, I; Laurent, M; Leissing-Desprez, C; Naga, H; Oubaya, N; Segaux, L, 2021
)
0.62
" However, its safe and efficacious use in elderly patients, a typical high bleeding risk cohort, in real world practice is yet to be reported."( Effectiveness and safety of bivalirudin in elderly patients with coronary artery disease undergoing percutaneous coronary intervention: A real-world study.
Han, Y; Li, J; Li, Y; Liu, X; Ma, S; Na, K; Qi, Z; Qiu, M; Xu, Y, 2022
)
0.72
" The primary outcome was 12-month net adverse clinical events (NACE) defined as a composite of cardiac death, myocardial infarction, stroke, revascularization, or any bleeding."( Effectiveness and safety of bivalirudin in elderly patients with coronary artery disease undergoing percutaneous coronary intervention: A real-world study.
Han, Y; Li, J; Li, Y; Liu, X; Ma, S; Na, K; Qi, Z; Qiu, M; Xu, Y, 2022
)
0.72
"The 48mm-EES is safe and effective to treat long coronary lesions, including CTOs, and provides attractive cost-effectiveness by limiting multiple stenting."( Safety and efficacy of 48 mm Xience Xpedition everolimus-eluting stent for the treatment of long coronary lesions.
Arroyo, D; Benamer, H; Champagne, S; Chevalier, B; Garot, P; Gautier, A; Hovasse, T; Lefèvre, T; Neylon, A; Sanguineti, F; Unterseeh, T, 2022
)
0.72
" Findings regarding adverse effects and outcomes were analyzed overall, for dogs grouped on the basis of life stage (mature adult, senior, or end of life), and for treatment-related or tumor-related variables to identify potential predictors of outcome."( Stereotactic radiotherapy (10 Gy X 3) for canine nonlymphomatous intranasal tumors is associated with prolonged survival and minimal risk of severe radiotoxicity.
Berman, AR; Gieger, TL; Marcus, KL; Nolan, MW; Olby, NJ; Quinn, CN; Russell, K; Watson-Skaggs, ML; Yoshikawa, H, 2022
)
0.72
"The ACT regimen in patients with HER2-negative BC was associated with an increased risk of adverse cardiactoxic events."( Grading Evaluation of Cardiotoxicity in Patients with Breast Cancer Treated with Adjuvant Paclitaxel Anthracycline/Cyclophosphamide Chemotherapy: A Meta-Analysis.
Hu, W; Li, L; Song, M, 2022
)
0.72
" Adverse events associated with psychedelics were reported as mild and transient."( A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
Blumberger, DM; Castle, DJ; Husain, MI; Ledwos, N; McIntyre, RS; Mulsant, BH; Rosenblat, JD,
)
0.13
" This case report demonstrates that it is necessary to evaluate not only the impact of immune-related adverse events on short-term quality of life during ICI treatment but also on the patient's end-of-life care."( End-of-life impact of concurrent diabetes mellitus and adrenal insufficiency as immune-related adverse events in an advanced non-small cell lung cancer patient.
Nakamura, T; Ohashi, K; Ohe, Y; Takeyasu, Y; Yoshida, T, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"To assess the prognostic value of pulse indicator continuous cardiac output (Picco) monitoring combined with plasma microRNA-150 detection in septic shock patients."( [Prognostic value of Picco monitoring combined with plasma microRNA-150 detection in septic shock patients].
Liu, HX; Shi, B; Wei, YJ; Wu, HY; Yang, WH; Zhang, HZ, 2015
)
0.42
"Lower microRNA-150 may indicate a poor prognosis, and Picco monitoring combined with microRNA 150 detection may improve the prognostic efficiency in septic shock patients."( [Prognostic value of Picco monitoring combined with plasma microRNA-150 detection in septic shock patients].
Liu, HX; Shi, B; Wei, YJ; Wu, HY; Yang, WH; Zhang, HZ, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" However, it cannot be excluded that co-administration of Pgp inhibitors such as ritonavir or paroxetine could increase MDMA, MDE and PMA bioavailability and also enhance brain entry leading to severe side effects."( P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.
Haefeli, WE; Ketabi-Kiyanvash, N; Mikus, G; Weiss, J, 2003
)
0.32
" Intravascular hemolysis leads to impaired bioavailability of nitric oxide (NO), mediated by NO scavenging by plasma oxyhemoglobin and by arginine degradation by plasma arginase."( Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.
Gladwin, MT; Kato, GJ; Little, JA; Machado, RF; McGowan, V; Morris, CR; Morris, SM; Nichols, JS; Poljakovic, M; Taylor, J; Wang, X, 2006
)
0.33
"The impact of ascorbate on oxidative stress-related diseases is moderate because of its limited oral bioavailability and rapid clearance."( Therapeutic treatment with ascorbate rescues mice from heat stroke-induced death by attenuating systemic inflammatory response and hypothalamic neuronal damage.
Chang, CY; Chen, JY; Chen, SH; Cheng, TJ; Hu, ML; Lin, MT, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" The dose-response pattern occurred among both the bereaved and the property-loss victims."( Psychiatric reactions to disaster: the Mount St. Helens experience.
Shore, JH; Tatum, EL; Vollmer, WM, 1986
)
0.27
" Nodal points, such as engagement, dosage of affect, and management of transference are described, and case illustrations provided."( Psychotherapy with survivors of the Beverly Hills Supper Club fire.
Grace, M; Green, BL; Lindy, JD; Titchener, J, 1983
)
0.27
"1 micrograms/ml) altered the dose-response curves of glutamate (1 microM-10 mM), by reducing by 36% of its maximal effect."( Biochemical and pharmacological studies on a lethal neurotoxic polypeptide from Phoneutria nigriventer spider venom.
Lebrun, I; Magnoli, F; Troncone, LR; Yamane, T, 1995
)
0.29
" Targeted disruption of the NEP locus in mice results in enhanced lethality to endotoxin shock with a pronounced gene dosage effect."( Neutral endopeptidase modulation of septic shock.
Bozza, M; Carroll, MC; Finco, O; Gerard, C; Gerard, NP; Kolakowski, LF; Lu, B; Zurakowski, D, 1995
)
0.29
" Birds were dosed intravenously with 10, 20, or 40 mouse lethal dose per kilogram body weight (MLD/kg) of type C botulism toxin and observed for 5 days."( Type C botulism in turkeys: determination of the median toxic dose.
Galey, FD; Jeffrey, JS; Kinde, H; Meteyer, CU; Rezvani, M, 1994
)
0.29
" These conclusions include the following: (1) neutron doses may be more important for Mayak workers than for Japanese A-bomb victims in Hiroshima and can be accounted for using an adjusted dose (which accounts for neutron relative biological effectiveness); (2) to account for dose-rate effects, normalized dose X (a dimensionless fraction of an LD50 or ED50) can be evaluated in terms of an adjusted dose; (3) nonlinear dose-response curves for the risk of death via the hematopoietic mode can be converted to linear dose-response curves (for low levels of risk) using a newly proposed dimensionless dose, D = X(V), in units of Oklad (where D is pronounced "deh"), and V is the shape parameter in the Weibull model; (4) for X < or = Xo, where Xo is the threshold normalized dose, D = 0; (5) unlike absorbed dose, the dose D can be averaged over different Mayak workers in order to calculate the average risk of death via the hematopoietic mode for the population exposed at Site A; and (6) the expected cases of death via the hematopoietic syndrome mode for Mayak workers chronically exposed during work shifts at Site A to gamma rays and neutrons can be predicted using ln(2)B M[D]; where B (pronounced "beh") is the number of workers at risk (criticality accident victims excluded); and M[D] is the average (mean) value of D (averaged over the worker population at risk, for Site A, for the time period considered)."( Evaluating the risk of death via the hematopoietic syndrome mode for prolonged exposure of nuclear workers to radiation delivered at very low rates.
Lyzlov, AF; Osovets, SV; Scott, BR, 1998
)
0.3
" The frequency of extra dosage also increased significantly, from 32 percent (opioid) and 40 percent (non-opioid) one week before death to 68 percent and 66 percent in the last 48 hours, respectively."( A prospective study on the dying process in terminally ill cancer patients.
Chihara, S; Ichiki, T; Inoue, S; Morita, T; Tsunoda, J,
)
0.13
" The dose-response has taken center stage ever since its formulation by Paracelsus."( Quantitative definition of toxicity: a mathematical description of life and death with dose and time as variables.
Rozman, KK, 1998
)
0.3
" As boron concentration is further increased, the dose-response curve becomes flat as homeostatic processes are active; this is followed at higher doses by a new adverse response that increases with increasing dose."( Toxicity of boron to rainbow trout: a weight-of-the-evidence assessment.
Loewengart, G, 2001
)
0.31
"9 with a dose-response pattern)."( Multifetal pregnancy in older women and perinatal outcomes.
Grainger, DA; Meikle, S; Trumble, A; Zhang, J, 2002
)
0.31
"Buprenorphine at high dosage became available in France in 1996, as a substitution treatment for heroin addicts."( A new series of 13 buprenorphine-related deaths.
Kintz, P, 2002
)
0.31
"IV injection of crushed tablets, a concomitant intake of psychotropics (especially benzodiazepines and neuroleptics) and the high dosage of the buprenorphine formulation available in France appear as the major risk factors for such fatalities."( A new series of 13 buprenorphine-related deaths.
Kintz, P, 2002
)
0.31
"Metronidazole was given in various dosage regimens to 97 patients having microscopically diagnosed trichomoniasis."( Trichomoniasis. Clinical trial of metronidazole (Flagyl).
MONROE, SE, 1963
)
0.24
" A more intensive dosing regimen (10 or 20 mg/kg twice daily for 4 days) was used to examine PMA/MDMA effects on cortical 5-HT content."( Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine.
Callaghan, PD; Daws, LC; Farrand, K; Hughes, P; Irvine, RJ; Salem, A, 2006
)
0.33
"The purpose of the current study was to establish dose-response relationships for the effects of a number of commonly used illicit stimulants and investigate the behavioral response to increased core temperature."( Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia.
Irvine, RJ; Jaehne, EJ; Salem, A, 2007
)
0.34
" This differed to the slopes of the dose-response curves where MDMA and PMA showed the steepest slope for the doses used followed by methamphetamine then cocaine."( Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia.
Irvine, RJ; Jaehne, EJ; Salem, A, 2007
)
0.34
" Compared with depression, all early adversities with the same 2 exceptions were significantly associated with schizophrenia; both frequency of abuse and number of types of abuse increased the risk of schizophrenia in a dose-response pattern, suggesting causality."( Early adverse experiences in schizophrenia and unipolar depression.
Nanni, RC; Pozzi, DM; Rubino, IA; Siracusano, A, 2009
)
0.35
" If these changes are not due to artifact, dosing of hypnotic or anesthetic drugs might be warranted."( Processed electroencephalogram during donation after cardiac death.
Auyong, DB; Gan, TJ; Habib, AS; Klein, SM; Olson, D; Roche, AM, 2010
)
0.36
" The type, dosage and administration period of neuroleptics, the clinical and laboratory findings; and prognosis were compared in terms of mortality."( Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death.
Onder, E; Tural, U, 2010
)
0.36
"All patients received 325 mg of aspirin and a loading dose of 600 mg of clopidogrel followed by a maintenance dosage of 325 mg/d of aspirin and 75 mg/d of clopidogrel for at least 6 months."( High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011
)
0.37
" We found that the lethality (resulting from photodamage) as a function of laser energy fluence fits a 3-region dose-response curve."( Pulse duration and energy dependence of photodamage and lethality induced by femtosecond near infrared laser pulses in Drosophila melanogaster.
Arkhipov, SN; Dantus, M; Lozovoy, VV; Saytashev, I; Winkler, N; Zuraski, K, 2012
)
0.38
" To reduce this incidence, in most studies, induction therapy with depleting anti-T-lymphocyte antibodies is coupled with a reduction of the dosage of the calcineurin inhibitor."( Effect of a single intraoperative high-dose ATG-Fresenius on delayed graft function in donation after cardiac-death donor renal allograft recipients: a randomized study.
Abrahams, AC; Hilbrands, LB; Hoitsma, AJ; Kho, MM; Sanders, JS; van den Hoogen, MW; van Dijk, M; van Zuilen, AD; Weimar, W, 2013
)
0.39
" Arguments for these perspectives refer to the following themes: intention, dosage of sedative drugs, unconsciousness, and the pace of the dying process."( Bridging the gap between continuous sedation until death and physician-assisted death: a focus group study in nursing homes in Flanders, Belgium.
Bilsen, J; Deliens, L; Deschepper, R; Mortier, F; Rys, S, 2015
)
0.42
" A dose-response relationship between adverse life events and physical health in general was evident but more so for heart disease and eyesight degeneration."( Adverse life events and health: a population study in Hong Kong.
Jowett, S; Karatzias, T; Yan, E, 2015
)
0.42
" In the present study, we examined whether the failure of dosage compensation was responsible for this sex-specific mortality."( Misdirection of dosage compensation underlies bidirectional sex-specific death in Wolbachia-infected Ostrinia scapulalis.
Ishikawa, Y; Kayukawa, T; Shinoda, T; Sugimoto, TN; Tsuchida, T, 2015
)
0.42
"61 h from healthy birds dosed intravenously at 5 mg/kg."( The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures.
Chipangura, J; Duncan, N; Galligan, TH; Green, RE; Naidoo, V; Taggart, MA; Wolter, K, 2018
)
0.48
" Intensified and standard dosage regimens of enteric-coated mycophenolate sodium (EC-MPS) were week 1, 2,160 vs."( Short-Term Intensified Dosage Regimen of Mycophenolic Acid is Associated with Less Acute Rejection in Kidney Transplantation from Donation after Circulatory Death.
Chen, J; Huang, H; Liu, G; Peng, W; Wu, J, 2018
)
0.48
" The authors investigated the route of administration, period, dosage of opioids, intensity of dyspnea-scored according to the Japanese version of the Support Team Assessment Schedule-and clinical course from a review of medical records."( Opioids for Relief of Dyspnea Immediately Before Death in Patients With Noncancer Disease: A Case Series Study.
Murakami, M, 2019
)
0.51
" We pooled data on utilization rate of analgesic and sedative drugs and summarized the dosing between the moment prior to withholding or withdrawal of life support and the moment before death."( Pain management during the withholding and withdrawal of life support in critically ill patients at the end-of-life: a systematic review and meta-analysis.
Cardenas, YR; Cuenca, JA; Díaz, DP; Durán-Crane, A; Fowler, C; Laserna, A; López-Olivo, MA; Nates, JL; O'Connell, K; Price, KJ; Sprung, CL; Urso, C, 2020
)
0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
" Inappropriate dosing may precipitate or worsen delirium/hallucinations."( Rotigotine patch prescription in inpatients with Parkinson's disease: evaluating prescription accuracy, delirium and end-of-life use.
Ibrahim, H; Pooley, J; Richfield, EW; Woodward, Z, 2021
)
0.62
" A fixed-effects model was used to estimate the dose-response and age-specific associations between HDI exposure and the collated outcome measure."( Association of Youth Age at Exposure to Household Dysfunction With Outcomes in Early Adulthood.
Andersen, SH, 2021
)
0.62
"To assess: (1) symptom prevalence from the use of anticipatory medicines in patients with idiopathic Parkinson's disease, (2) the prescribing of antiparkinsonian medication at the end of life; and (3) the accuracy of conversion from oral antiparkinsonian medicines to transdermal rotigotine and any associations between rotigotine dosing and end-of-life symptoms."( Idiopathic Parkinson's Disease at the End of Life: A Retrospective Evaluation of Symptom Prevalence, Pharmacological Symptom Management and Transdermal Rotigotine Dosing.
Hindmarsh, J; Hindmarsh, S; Lee, M, 2021
)
0.62
" Numerous studies have demonstrated the positive association of high-sensitivity cardiac troponin T (hs-cTnT) and I (hs-cTnI) with all-cause and cardiovascular (CV) mortality in patients with kidney disease; however, the dose-response meta-analysis has not been reported."( High-sensitivity cardiac troponin, a cardiac marker predicting death in patients with kidney disease: a dose-response meta-analysis of cohort studies.
Chen, C; Feng, Y; Hu, D; Hu, F; Hu, H; Li, T; Li, X; Li, Y; Liu, Y; Sun, X; Wu, Y; Yang, XJ; Yuan, L; Zhang, J; Zhang, M; Zhao, Y, 2023
)
0.91
" Practical issues concerning PS-for example, prevalence, type and dosage of medications, salvage medication, timing of its initiation, and assessment-are described in detail."( Palliative Sedation in End-of-Life Patients in Eastern Asia: A Narrative Review.
Kang, JH; Kwon, JH; Lee, SH; Won, YW, 2022
)
0.72
" There are many challenges in conducting studies in advanced cancer with significant attrition and small sample sizes, however it is hoped that the results of our study will contribute to the evidence base and allow for continued development of gene-drug dosing guidelines for clinicians."( Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.
Albury, CL; George, R; Good, P; Griffiths, LR; Hardy, J; Haupt, LM; Haywood, A; Ozberk, D; Sutherland, HG; Yu, C; Zunk, M, 2022
)
0.72
" Tertiles for the Gini coefficient and social mobility were created to evaluate the dose-response association."( County-Level Income Inequality, Social Mobility, and Deaths of Despair in the US, 2000-2019.
Kawachi, I; Kuo, CT, 2023
)
0.91
" We observed a consistent dose-response relationship between an earlier gestational age and elevated risks of increasingly complex multimorbidity in both datasets."( Preterm birth and the risk of multimorbidity in adolescence: a multiregister-based cohort study.
Heikkilä, K; Kajantie, E; Kivimäki, M; Metsälä, J; Nilsen, SM; Pulakka, A; Risnes, K, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki33.60000.00020.667710.0000AID5270
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki33.60000.00010.601710.0000AID5270
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki79.40000.00010.739610.0000AID3695
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki79.40000.00031.29679.2440AID3695
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Ki79.40000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Ki79.40000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki33.60000.00020.590910.0000AID5270
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)0.17300.00030.81978.4900AID471630
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd7.07950.00042.58328.5114AID6405; AID6406
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd7.07950.00012.62198.5114AID6405; AID6406
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd7.07950.00012.29338.5114AID6405; AID6406
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Kd7.07950.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Kd7.07950.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Kd7.07950.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd7.07950.00042.47358.5114AID6405; AID6406
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Kd7.07950.02342.74218.5114AID6405; AID6406
Sodium-dependent serotonin transporterHomo sapiens (human)EC50 (µMol)551.93970.00112.38838.7000AID471635; AID471638
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Kd7.07950.00012.70068.5114AID6405; AID6406
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Kd7.07950.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Kd7.07950.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Kd7.07950.00082.62148.5114AID6405; AID6406
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Kd7.07950.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Kd7.07950.00082.62148.5114AID6405; AID6406
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID471635Induction of human SERT-dependent cytotoxicity in SERT expressing HEK293 cells after 48 hrs by neutral red assay2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.
AID188587Number of rats responding out of 5 treated rats at a dose of 1.5 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID1131956Hallucinogenic activity in human1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Structure-activity studies on hallucinogenic amphetamines using molecular connectivity.
AID88883Hallucinogenic activity i.e; ratio of effective dose of mescaline to the effective dose in human1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID5797Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID5270Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID241440Inhibitory concentration against monoamine oxidase A in rat brain mitochondrial suspension2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling.
AID471630Inhibition of [3H]5-HT reuptake at rat SERT expressed in HEK293 cells after 2 mins by liquid scintillation counting2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.
AID90250Human hallucinogenic activity relative to mescaline1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID23503Partition coefficient (logP)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID175575Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 4 mg/kg; Disruption behavior1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID188586Number of rats responding out of 5 treated rats at a dose of 1 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID471634Cytotoxicity against human HEK293 cells after 48 hrs by neutral red assay2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.
AID6405Binding affinity at rat 5-hydroxytryptamine receptor.1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID175416Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 0.5 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID91217Compound tested for hallucinogenic activity in humans was reported; Value reported in (A)= Mescaline units1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.
AID395043Inhibition of MAOA in rat brain mitochondria2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors.
AID1136504Inhibition of PNMT in rabbit adrenal gland using norepinephrine as substrate1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
A manual method for applying the Hansch approach to drug design.
AID395041Inhibition of MAOB in rat brain mitochondria at 100 uM2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors.
AID6406Affinity against 5-hydroxytryptamine receptors in rat fundus model1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Serotonin receptor affinities of psychoactive phenalkylamine analogues.
AID175419Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 1 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID227926Equilibrium constant for DNB complex formation1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID3695Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID188584Number of rats responding out of 5 treated rats at a dose of 0.5 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID471639Cytotoxicity against human SH-SY5Y cells after 48 hrs by neutral red assay2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.
AID471638Induction of human SERT-dependent cytotoxicity in SERT expressing human DG75 cells after 48 hrs by neutral red assay2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.
AID19263Log value of hallucinogenic activity was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18,256)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907914 (43.35)18.7374
1990's1720 (9.42)18.2507
2000's2012 (11.02)29.6817
2010's3946 (21.61)24.3611
2020's2664 (14.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.08 (24.57)
Research Supply Index9.94 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials245 (1.20%)5.53%
Reviews1,116 (5.47%)6.00%
Case Studies1,139 (5.58%)4.05%
Observational176 (0.86%)0.25%
Other17,731 (86.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]